Methylene Blue-Photodynamic Therapy for Burns

This trial tests a new treatment for burn wounds at risk of infection. Methylene Blue-Photodynamic Therapy combines methylene blue, a dye, with blue light to kill bacteria in wounds. Participants will receive either this new treatment or just blue light during regular dressing changes to assess its effectiveness in reducing infections and improving healing. Individuals with partial- or full-thickness burns requiring dressing changes for at least a week may qualify. The trial will also evaluate the treatment's safety and comfort. As a Phase 1 and Phase 2 trial, this research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering participants a chance to benefit from this innovative approach.

If you are currently taking SSRIs, SNRIs, monoamine oxidase inhibitors, or other serotonergic medications, you will need to stop taking them to participate in this trial.

Research has shown that methylene blue-photodynamic therapy (MB-PDT) is generally easy for patients to handle. In past studies, patients who received this treatment experienced less wound fluid without any harmful local reactions, suggesting the therapy is safe for treating burns. Other research supports its safety, indicating that MB-PDT can reduce smell, fluid leakage, and wound size. Most patients tolerated the treatment well.

Unlike the standard burn care treatments, which typically involve topical antibiotics and regular dressing changes, Methylene Blue-Photodynamic Therapy stands out with its unique approach. This therapy uses methylene blue, a dye that, when exposed to blue light, generates reactive oxygen species to target and kill harmful bacteria in burn wounds. This mechanism could potentially speed up healing and reduce infection risk. Researchers are excited about this treatment because it combines a straightforward application with a novel light-activated action, offering a promising alternative to conventional methods.

Research has shown that methylene blue-photodynamic therapy (MB-PDT), which participants in this trial may receive, can effectively reduce bacterial infections in burn wounds. Studies indicate that it speeds up healing by lowering inflammation markers like TNF-α and IL-6 and boosting growth factors that aid recovery. In trials, patients experienced a significant reduction in wound size and fewer infection-related symptoms, such as bad odor. MB-PDT has also successfully treated infections from difficult-to-treat bacteria. Overall, MB-PDT appears promising as a non-antibiotic treatment for burn wound infections.¹³⁴⁵⁶